Bicuculline from

Xiaozheng Zhang, Guicai Wu, Sili Peng, Haoran Xu, Kai Li, Tingjuan Huang, Zhizhen Liu

Abstract read

In one paragraph

Article in Computational and structural biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiaozheng ZhangDepartment of Biochemistry and Molecular Biology, College of Basic Medicine; Shanxi Key Laboratory of Birth Defect and Cell Regeneration; MOE Key Laboratory of Coal Environmental Pathogenicity and Prevention, Shanxi Medical University, Taiyuan 030001, China.

Guicai WuDepartment of Biochemistry and Molecular Biology, College of Basic Medicine; Shanxi Key Laboratory of Birth Defect and Cell Regeneration; MOE Key Laboratory of Coal Environmental Pathogenicity and Prevention, Shanxi Medical University, Taiyuan 030001, China.

Sili PengDepartment of Biochemistry and Molecular Biology, College of Basic Medicine; Shanxi Key Laboratory of Birth Defect and Cell Regeneration; MOE Key Laboratory of Coal Environmental Pathogenicity and Prevention, Shanxi Medical University, Taiyuan 030001, China.

Haoran XuDepartment of Biochemistry and Molecular Biology, College of Basic Medicine; Shanxi Key Laboratory of Birth Defect and Cell Regeneration; MOE Key Laboratory of Coal Environmental Pathogenicity and Prevention, Shanxi Medical University, Taiyuan 030001, China.

Kai LiState Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, China.

Tingjuan HuangDepartment of Biochemistry and Molecular Biology, College of Basic Medicine; Shanxi Key Laboratory of Birth Defect and Cell Regeneration; MOE Key Laboratory of Coal Environmental Pathogenicity and Prevention, Shanxi Medical University, Taiyuan 030001, China.

Zhizhen LiuDepartment of Biochemistry and Molecular Biology, College of Basic Medicine; Shanxi Key Laboratory of Birth Defect and Cell Regeneration; MOE Key Laboratory of Coal Environmental Pathogenicity and Prevention, Shanxi Medical University, Taiyuan 030001, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver fibrosis, a cardinal feature of chronic liver injury, involves hepatic stellate cells (HSCs) activation and excessive extracellular matrix (ECM) deposition. Upon liver fibrosis, TLR4 is highly expressed on HSCs and Kupffer cells. TLR4 activation induces liver inflammation followed by exacerbated fibrosis. Inhibition of TLR4 signaling represents a validated anti-liver fibrosis therapeutic approach. In the realm of liver fibrosis treatment, traditional Chinese medicine (TCM) has demonstrated certain anti-fibrotic effects in clinical practice after long-term application. However, due to the complex composition of TCM, understanding the underlying biological mechanisms and controlling drug quality remain challenging. To address these issues, this study developed a database of potential active ingredients from TCM against liver fibrosis and conducted virtual screening based on TLR4/MD2. It is worth noting that bicuculline, a known GABA

Indexed as

Liver fibrosisMolecular dynamics simulationTCM prescription miningToll-like receptor 4

Identifiers

PMID41585934

DOI10.1016/j.csbj.2025.12.026

PMCPMC12829150

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.